Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125902 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 653
- Enrollment target
NCT03125902 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 653 participants.
The verdict
NCT03125902, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 653 participants
- Enrollment target
Study Summary
This Phase 3, multicenter, randomized, double-blind, placebo controlled study is designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-programmed death-ligand 1 \[PD-L1\] antibody) administered in combination with paclitaxel compared with placebo in combination with paclitaxel in participants with previously untreated, inoperable locally advanced or metastatic, centrally confirmed TNBC. Participants will be randomized in a 2:1 ratio to receive atezolizumab or placebo plus paclitaxel until disease progression or unacceptable toxicity or end of study, whichever occurs first (maximum up to approximately 40 months). In addition, the Sponsor may decide to terminate the study at any time.
Interventions
- DRUG Paclitaxel
- DRUG Atezolizumab Placebo
- DRUG Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 653 participants |
| Start Date | 2017-08-25 |
| Est. Completion | 2023-01-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03125902
The ClinicalTrials.gov registry entry for NCT03125902 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 653 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT03125902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03125902 about?
NCT03125902 is a clinical study titled "A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)". This Phase 3, multicenter, randomized, double-blind, placebo controlled study is designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-programmed death-ligand 1 \[PD-L1\] antibody) administered in combination with paclitaxel compared with placebo in combination with paclit...
What is the current status of trial NCT03125902?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 653 participants. The study started on 2017-08-25. Estimated completion is 2023-01-17.
What interventions are being tested in trial NCT03125902?
The interventions under investigation include: Paclitaxel (DRUG), Atezolizumab Placebo (DRUG), Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody (DRUG).
Who is sponsoring clinical trial NCT03125902?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.